Non-malignant cells coupled to adjuvants and their use in a method to induce anti-tumor immunity
AssigneeState University of New York (Suny)
InventorArnold E. Eggers
Life of this patent
Estimating the term…
Abstract
A vaccine composition for inducing anti-tumor immunity comprising non-malignant cells, preferably syngeneic mon-malignant cells, coupled with adjuvant compounds. The nonmalignant immunizing cells of the present invention induce T-cell mediated cytoxicity which cross-reacts with tumor cells, providing in vivo protection against the tumor cells. Examples of turmors which may be treated by administration of the vaccine compositions include fibrosarcomas, glioblastomas, and all solid and lymphoid tumors.
Claims26
A vaccine composition for inducing immunity in a mammal against a tumor selected from the group consisting of sarcomas, gliomas, and carcinomas, comprising a therapeutically effective amount of non-malignant mammalian fibroblast cells covalently coupled with an adjuvant in a pharmaceutically acceptable medium, said adjuvant selected from the group consisting of muramyl dipeptide, the p-nitrophenyl ester of muramyl dipeptide (N-acetylmuramyl-L-alanyl-D-isoglutamine), the p-nitrophenyl ester of cord factor analog, and other adjuvants derived from or synthesized to resemble components of bacterial or fungal cell walls which have a reactive carboxyl, amino, or sulfhydryl group capable of activation for vonalent coupling to cells.
A method for inducing immunity against a tumor selected from the group consisting of sarcomas, gliomas, and carcinomas, in a mammal which comprises administering to the mammal a therapeutically effective amount of a vaccine composition comprising nonmalignant mammalian fibroblast cells covalently coupled with an adjuvant selected from the group consisting of muramyl dipeptide, the p-nitrophenyl ester of muramyl dipeptide (N-acetylmuramyl-L-alanyl-D-isoglutamine), the p-nitrophenyl ester of cord factor analog, or other adjuvants derived from or synthesized to resemble components of bacterial or fungal cell walls which have a reactive carboxyl, amino, or sulfhydryl group capable of activation for covalent coupling to cells.
A method according to clam 15 wherein the mammal is a human and the non-malignant cells are human fibroblasts.
Dependencies are inferred from the claim text.